If peer review was a drug it would never be allowed onto the market, ' says Drummond Rennie, deputy editor of the Journal Of the American Medical Association and intellec tual father of the international congresses of peer review that have been held every four years since 1989. Peer review would not get onto the market because we have no convincing evidence of its benefi ts but a lot of evidence of its fl aws.
No takes yet. Share an insight, caveat, or question.
Richard Smith (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: